AbbVie Inc. (NYSE:ABBV) is listed among the 12 Best Stocks to Buy for the Long Term. Citi recently adjusted its price target for AbbVie to $230 from $235 and left its Neutral rating unchanged, citing a more supportive backdrop for the biopharma sector in 2026.

While facing disappointing clinical news, AbbVie’s blood cancer drug epcoritamab did not show a clear survival benefit in a late-stage study. However, the study did show promising results such as more patients achieving undetectable cancer and longer-lasting responses.

Epcoritamab, already approved in several countries for other lymphoma indications, is sold as Epkinly in the U.S. and Japan and as Tepkinly in the European Union. AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on developing and bringing new medicines to market.

Despite the potential of AbbVie as an investment, some believe other AI stocks offer greater upside potential with less downside risk. For those seeking an undervalued AI stock with potential benefits from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available for review.

Read more at Yahoo Finance: Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma